37 results about "Pharmaceutical solvent" patented technology

A pharmaceutical delivery system for oral inhalation is disclosed through nebulization consisting of an inert supporting material impregnated with or deposited with pharmaceutically active ingredient which must be solubilized or suspended in a pharmaceutical solvent to form a solution or suspension prior to administration. Each pharmaceutical delivery unit dosage form comprises one or more therapeutically effective and safe amounts of pharmaceutically active ingredient uniformly impregnated in or deposited on a supporting material which is a natural or synthetic polymer, woven or non-woven fabrics, inert paper, inorganic materials such as foil and combination thereof in a single or multi-layer lamination in a form of a sheet or strip or film or membrane or sponge-like or cup or well. The dosage form of this invention is to be administered to a patient through oral or nasal inhalation using a nebulizer after reconstitution with a reconstituting solvent.

The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating musculoskeletal pain, inflammation, joint pain, etc. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time.

The present invention relates to a solvent system with improved disintegration degree and dissolution ratio of a hardly soluble drug by highly concentrating the drug through partial ionization, and by establishing optimal conditions for enhancing bioavailability of the drug, such as the co-relation between the acid drug and the accompanied components, ionization degree of a solvent system, use of an appropriate cation acceptor, water content, selection of optimal mixing ratio of the respective components and use of specific surfactants, and to a pharmaceutical preparation comprising the same. The solvent system of the invention has advantages in that it can enhance bioavailability by improving the disintegration degree and dissolution ratio of a hardly soluble drug and also provide a capsule with a sufficiently small volume to permit easy swallowing.

The invention discloses a percutaneous give drug system, which comprises: a drug storeroom, the gel drug layer comprises drug, solvent, transdermal accelerating agent and gelatinizing agent; one adsorption layer comprised solvent absorption material of solvent in absorbable drug storeroom; one isolating layer between drug storeroom and adsorption layer, which is of non-woven fabrics or semipermeable membrane to make solvent of gas or liquid pass through successfully; adsorption layer can joint isolating layer of drug storeroom in opposite directions of closing up to skin of drug storeroom. The percutaneous give drug system in this invention can increase drug level in drug storeroom of the system to elevate drug transdermal speed, as well as increase controlled release effect of percutaneous give drug and absolute bioavailability, enhance drug curative effect, decrease drug waste, and depress preparation cost of the system. The invention is fit particular to percutaneous give drug system for water-soluble drug of propranolol hydrochloride, verapamil hydrochloride and chlorpromazine hydrochloride.

The invention discloses a lacosamide oral solution and a preparation method of the lacosamide oral solution and belongs to the field of pharmaceutical preparations. The lacosamide oral solution comprises lacosamide, an appropriate medicine solvent system, one or more flavoring agents, one or more preservatives, one or more acid-base modifiers, one or more solubilizers and one or more thickeners. The lacosamide oral solution is stable in performance, good in taste, rapid in absorption, capable of acting rapidly and good in curative effect.

The invention discloses a patch for treating rheumatic arthritis and a preparation method thereof. The patch consists of a main medicament for treating rheumatic arthritis, a medicament solvent, a substrate and a penetrating agent, wherein the main medicament consists of triptolide and lidocaine serving as a pain-relieving medicament for relieving rheumatic arthritis pain. The patch is medical controlled-release slow release preparation, has a comprehensive pharmacological action, is used for blocking major development pathologic loops of the rheumatic arthritis disease, and has high specificity and a lasting pharmacological effect; and the preparation method is simple.

The Qingkailing preparation for great transfusion is prepared with cholic acid 1.2-2.0 weight portions, hyodeoxycholic acid 1.4-2.4 weight portions, buffalo horn 9-16 weight portions, baicalin 1.8-3.2 weight portions, nacre 18-32 weight portions, cape jasmine 9-16 weight portions, isatis root 75-125 weight portions, and honeysuckle 23-38 weight portions. It is prepared through extraction, hydrolysis, mixing, filtering, active carbon treatment, sterilizing and other steps. The Qingkailing preparation for great transfusion has high clarity, high stability, high safety and other advantages, and is suitable for medical care personnel to use.

The invention relates to a contraceptive and a preparation method thereof. The present invention provides a hormonal contraceptive, and a chemical contraception prescription. An oral contraceptive hormone is dissolved or dispersed in an organic pharmaceutical solvent to prepared a stock solution; an external contraceptive is dissolved in purified water or a pharmaceutically acceptable solid carrier to dissolve the drug into a preparation; and the stock solution containing the oral contraceptive and prepared mixture containing external contraceptive are mixed. The present invention overcomes the respective defects of oral contraceptive and external contraceptive. The contraceptive takes the respective advantages of the oral and external contraceptives, and uses good drug absorption of the female vagina, especially sensitivity and dependence on hormone drugs to combine the characteristics of oral contraceptive and external contraceptive. The contraceptive creatively combines the two to avoid drug stimulation on the gastrointestinal tract, avoid the drug inactivation caused by liver first-pass metabolism, also reduce the dose, and form a novel pharmaceutical prescription.

The invention relates to a device (10) for storing and extemporaneously preparing, before administration, at least one active principle, which includes: A body (12), comprising at least one compartment for containing at least one lower volume of 5 ml of pharmaceutical solvent (22); a head (14), comprising at least one compartment for containing at least one active principle (24), particularly a very low dose, and comprising, in the upper portion thereof, of at least one collection chamber (32) provided with a filter (40), said head (14) capable of taking a first storing position P1, wherein said head (14) is in a distal position relative to the body (12), and a second preparation position P2, wherein said head (14) is in a proximal position relative to the body (12), at least one partition (16) separating the body (12) and the head (14); and a rupturing means (18) for rupturing said partition (16) such that the active principle (24) comes into contact with the solvent (22) and dissolves into the latter. The invention also aims to use said device to store and extemporaneously prepare at least one active principle with a view to administer the same.

The invention relates to the field of natural drugs and chemical drugs and particularly relates to application of a novel 19-demethyl resibufogenin compound to preparation of an antitumor pharmaceutical preparation. The novel 19-demethyl resibufogenin compound has a structure as shown in the formula I, is named as Bufogargarin A and is extracted and separated from toad skin. The Bufogargarin A disclosed by the invention has remarkable antitumor activity in vitro and vivo and is not observed to have remarkable toxic or side effects under a therapeutic dose so as to have a favorable pharmaceutical prospect and be applied to preparation of the antitumor pharmaceutical preparation. The antitumor pharmaceutical preparation contains Bufogargarin A and the balance of pharmaceutical auxiliary materials or other compatible drugs; the pharmaceutical auxiliary materials can be various pharmaceutical solvents, disintegrating agents, flavoring agents, preservatives, colorants and binding agents; and the antitumor pharmaceutical preparation includes various clinical dosage forms.

The invention relates to a pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)ammonium chloride in the monohydrate form or in unhydrated form. The pharmaceutical further comprises dimethyl(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl(3-[myristoylamino]propyl)amine in the appropriate pharmaceutical solvent.

The invention discloses application of formononetin to preparation of drugs for treating pulmonary hypertension and the drugs for treating pulmonary hypertension. The pulmonary hypertension drugs areoral drugs or injection drugs. The pulmonary hypertension drugs in the form of injection drugs are obtained by dissolving the formononetin in pharmaceutical solvents. The pharmaceutical solvents comprise dimethyl sulfoxide and/or olive oil. According to the present invention, the proliferation of pulmonary artery smooth muscle cells can be inhibited and the apoptosis of the pulmonary artery smoothmuscle cells can be promoted by the formononetin, pulmonary vascular remodeling can be significantly improved, pulmonary vascular resistance and pulmonary artery pressure can be reduced, the formononetin plays a role in reducing blood pressure stably, pulmonary function and right heart function can be restored, human impaired function can be normalized and complications can be treated as a whole.

The invention discloses a compound acne solution and a preparation method thereof. The preparation method comprises: S100, preparing a drug solvent: taking borneol and a soaking liquid, placing in a container, dissolving, uniformly stirring, and sealing; S200, preparing seven-component powder: taking calcined gypsum, Radix Puerariae, Folium Hibisci Mutabilis, Angelica dahurica, peppermint, Fritillaria thunbergii and Arisaema Cum Bile, and preparing seven-component powder; S300, leaching: adding the seven-component powder into the drug solvent, uniformly mixing, and soaking for 7-15 days in a sealed dark and cool place; S400, filtering: removing the residue through filtering, and adding glycerin to the filtrate; and S500, storing: storing in a sealed dark and cool place. According to the present invention, the compound acne solution has advantages of quick effect, short treatment course, wide application range and the like; and the preparation method is simple in process, and can save alarge amount of manpower and material resources.

The invention provides a rapamycin self-microemulsion injection. The rapamycin self-microemulsion injection consists of a medicine mother solution and a diluent, the medicine mother liquor comprises a medicine solvent, an antioxidant and rapamycin; the diluent comprises a surfactant and water. The rapamycin self-microemulsion injection provided by the invention consists of a medicine mother solution and a diluent, the rapamycin is dissolved in the drug solvent, after the diluent and the mother liquor are mixed and diluted, the liquid is self-assembled to form the micro-emulsion under the action of the surfactant, and meanwhile, the rapamycin is encapsulated in the micro-emulsion, so that the solubility of the rapamycin is improved, and the stability of the rapamycin is also improved.